User:Ivan E. Wang/Sandbox 1
From Proteopedia
(Difference between revisions)
| Line 20: | Line 20: | ||
== Exogenous Ligand == | == Exogenous Ligand == | ||
=== (''R'')-Emixustat (ACU-4429) === | === (''R'')-Emixustat (ACU-4429) === | ||
| - | |||
| - | <StructureSection load='4rry' size='340' side='left' caption='(''R'')-emixustat bound in the active site of RPE65' scene=''> | ||
(''R'')-emixustat (ACU-4429) is an investigational small molecule inhibitor of RPE65 first invented by a British-American chemist, Ian L. Scott. Formulated as an hydrochloride salt, (''R'')-emixustat hydrochloride is taken by mouth and functions as a visual cycle modulator (VCM) to reduce toxic retinal byproducts such as A2E. | (''R'')-emixustat (ACU-4429) is an investigational small molecule inhibitor of RPE65 first invented by a British-American chemist, Ian L. Scott. Formulated as an hydrochloride salt, (''R'')-emixustat hydrochloride is taken by mouth and functions as a visual cycle modulator (VCM) to reduce toxic retinal byproducts such as A2E. | ||
In 2008, Acucela Inc. partnered with Otsuka Pharmaceutical Company for the continued development of (''R'')-emixustat as a potential inhibitor of RPE65. Currently (''R'')-emixustat is in Phase III clinical trials in the United States for the potential treatment of Stargard's disease, a juvenile form of atrophic (dry) age dependent macular degeneration (AMD). Additionally, (''R'')-emixustat is investigated as potential therapy for diabetic retinopathy and diabetic macular edema. | In 2008, Acucela Inc. partnered with Otsuka Pharmaceutical Company for the continued development of (''R'')-emixustat as a potential inhibitor of RPE65. Currently (''R'')-emixustat is in Phase III clinical trials in the United States for the potential treatment of Stargard's disease, a juvenile form of atrophic (dry) age dependent macular degeneration (AMD). Additionally, (''R'')-emixustat is investigated as potential therapy for diabetic retinopathy and diabetic macular edema. | ||
| + | |||
| + | <StructureSection load='4rry' size='340' side='left' caption='(''R'')-emixustat bound in the active site of RPE65' scene=''> | ||
=== (''S'')-Emixustat === | === (''S'')-Emixustat === | ||
Revision as of 21:34, 28 January 2020
Retinal Pigment Epithelium 65 (Retinoid Isomerohydrolase) complex with (R/S)-emixustat and palmitate
| |||||||||||
References
- ↑ Hanson, R. M., Prilusky, J., Renjian, Z., Nakane, T. and Sussman, J. L. (2013), JSmol and the Next-Generation Web-Based Representation of 3D Molecular Structure as Applied to Proteopedia. Isr. J. Chem., 53:207-216. doi:http://dx.doi.org/10.1002/ijch.201300024
- ↑ Herraez A. Biomolecules in the computer: Jmol to the rescue. Biochem Mol Biol Educ. 2006 Jul;34(4):255-61. doi: 10.1002/bmb.2006.494034042644. PMID:21638687 doi:10.1002/bmb.2006.494034042644
